From Human Papillomavirus to Cervical Cancer

American College of Obstetrics and Gynecology

July 10, 2010

Mark Schiffman, MD, MPH, and Nicolas Wentzensen, MD, PhD
Cervical cancer is one of the most common female
malignancies worldwide; 80% of cases occur in
low-resource regions.1,2 Screening programs have been
very successful in the United States, Europe, and other
regions able to achieve broad and sustained coverage. In
the United States, the disease is controlled at an annual
cost of billions of dollars representing a major commitment
by patients and clinicians. In fact, cervical cancer
screening and management of minor screening abnormalities
are among the most time-time-consuming parts of
some gynecology practices.
Cervical cancer prevention can now be made even
better. Substantial modifications of practice are forthcoming,
motivated by improved understanding of human
papillomavirus (HPV) natural history and cervical
carcinogenesis. In this update, we will summarize the
new knowledge and its possible implications in the
United States.



Author: Leslie Carol Botha

Author, publisher, radio talk show host and internationally recognized expert on women's hormone cycles. Social/political activist on Gardasil the HPV vaccine for adolescent girls. Co-author of "Understanding Your Mood, Mind and Hormone Cycle." Honorary advisory board member for the Foundation for the Study of Cycles and member of the Society for Menstrual Cycle Research.